Harmonization of Technical Requirements for Pharmaceuticals for Human Use (U01) | Apply Online

Opportunity Summary:

The grant opportunity "Harmonization of Technical Requirements for Pharmaceuticals for Human Use (U01)" is an FDA cooperative agreement designed to support the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) in bringing together major drug regulatory authorities and pharmaceutical industry associations from around the world. The central aim is to strengthen and expand global alignment on technical requirements used to develop, evaluate, and register medicines, so that safe, effective, and high-quality drugs can reach patients with less duplication of effort and more efficient use of scientific and regulatory resources. In practical terms, FDA is funding the coordination work needed to convene experts, facilitate consensus building, and produce internationally accepted guidelines that regulators and manufacturers can rely on across multiple regions.

A key feature of this announcement is that it is explicitly a single-source opportunity. Only ICH is eligible to apply, and FDA stated its intent to consider and accept only one application for one award. The mechanism is a cooperative agreement (U01), which generally signals substantial federal involvement beyond a standard grant, often including collaboration, shared planning, or ongoing programmatic coordination between the awardee and the agency. The opportunity falls under the broad activity category of consumer protection, food and nutrition, and health, and it is administered through the Food and Drug Administration under CFDA (now commonly referred to as Assistance Listing) 93.103.

The expected output of the funded work is a set of harmonized, internationally recognized ICH guidelines organized into four main technical areas: Quality, Safety, Efficacy, and Multidisciplinary topics. In the Quality domain, the focus is on shared expectations for pharmaceutical quality and manufacturing controls, including widely used standards for stability studies, consistent approaches to impurity identification and acceptable thresholds, and modern quality systems grounded in Good Manufacturing Practice (GMP) and risk management principles. These types of guidelines help ensure that a product manufactured and tested under one region's expectations can be more readily understood and trusted by regulators in another region, reducing the need to repeat studies solely to satisfy different formatting or technical conventions.

In the Safety area, the opportunity emphasizes guidelines that help detect and characterize potential toxicological risks before and during human use. This includes frameworks for evaluating carcinogenicity, genotoxicity, and reproductive and developmental toxicity (often grouped under reprotoxicity). Harmonized safety guidelines matter because preclinical programs are expensive and time-consuming, and divergent national requirements can force sponsors to run additional studies that do not necessarily improve patient safety. International alignment can preserve high safety standards while minimizing redundant testing and encouraging consistent interpretation of safety signals.

Under Efficacy, ICH work supported by this program is centered on clinical trial design, conduct, monitoring of safety within trials, and consistent reporting of outcomes. This area also covers scientific and regulatory approaches for newer categories of therapies, including medicines produced through biotechnology, as well as the integration of pharmacogenetics and pharmacogenomics to improve how treatments are targeted to specific patient populations. Harmonization here supports more globally accepted trial designs and data packages, enabling companies to plan multinational development programs that meet expectations in multiple jurisdictions and helping regulators compare results using shared definitions and reporting standards.

The Multidisciplinary category covers cross-cutting standards that do not fit neatly into quality, safety, or efficacy alone. Two prominent examples named in the announcement are the Common Technical Document (CTD), which standardizes the structure and content of marketing application submissions, and ESTRI (Electronic Standards for the Transfer of Regulatory Information), which promotes consistent electronic formats and data exchange standards. These tools directly reduce friction in regulatory submissions by making the organization of information and the electronic transmission of regulatory data more consistent worldwide, improving review efficiency and lowering administrative burden for both sponsors and regulators.

From a funding and timing standpoint, the total estimated funding for the opportunity is $500,000, with an award ceiling of $500,000 and an expectation of a single award. There is no cost-sharing or matching requirement. The opportunity was posted on May 18, 2015, with an original and current closing date of September 30, 2015, and an archive date of October 30, 2015. Additional details were referenced through a Federal Register notice for RFA FD 15 014. For administrative or access issues, the grants management contact listed is Lisa Ko at lisa.ko@fda.hhs.gov.

Overall, this cooperative agreement is best understood as targeted support for ICH's convening power and consensus-driven guideline development, with FDA backing a coordinated international process that yields practical standards used across the lifecycle of medicine development. The intended public health impact is broader and more consistent global regulation, fewer unnecessary barriers to registration, and a more efficient pathway to delivering high-quality medicines while maintaining rigorous scientific and safety expectations.

Browse more opportunities from the same agency: Food Drug Administration

Browse more opportunities from the same category: Consumer Protection Food and Nutrition Health

Next opportunity: Cross Bar Management Area Archaeological Field School

Previous opportunity: Predominantly Black Institutions Competitive Grant Program CFDA Number 382A

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA FD 15 014

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (RFA FD 15 014) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA FD 15 014", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.